Shares of Kezar Life Sciences Inc (NASDAQ:KZR) have earned a consensus rating of “Hold” from the seven research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $15.00.

A number of analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Kezar Life Sciences in a report on Thursday, August 6th. ValuEngine cut shares of Kezar Life Sciences from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 4th. Wells Fargo & Co restated a “market perform” rating and set a $18.00 target price on shares of Kezar Life Sciences in a report on Sunday, June 14th. Cowen restated an “outperform” rating on shares of Kezar Life Sciences in a research report on Sunday, June 14th. Finally, BidaskClub downgraded shares of Kezar Life Sciences from a “sell” rating to a “strong sell” rating in a research report on Friday, June 5th.

Shares of NASDAQ:KZR opened at $4.48 on Tuesday. The stock has a market capitalization of $212.80 million, a price-to-earnings ratio of -2.99 and a beta of 0.04. Kezar Life Sciences has a 1-year low of $2.18 and a 1-year high of $9.79. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.69 and a current ratio of 18.69. The company has a 50 day moving average price of $4.99 and a 200 day moving average price of $4.72.

Kezar Life Sciences (NASDAQ:KZR) last issued its earnings results on Wednesday, August 5th. The company reported ($0.22) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.04. On average, sell-side analysts expect that Kezar Life Sciences will post -1.13 EPS for the current fiscal year.

In other Kezar Life Sciences news, Director Franklin M. Berger purchased 100,000 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were bought at an average price of $4.84 per share, for a total transaction of $484,000.00. Following the purchase, the director now directly owns 784,003 shares in the company, valued at approximately $3,794,574.52. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Equal Talent Investments Ltd purchased 1,454,545 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were acquired at an average price of $5.50 per share, for a total transaction of $7,999,997.50. The disclosure for this purchase can be found here. Corporate insiders own 7.60% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Franklin Resources Inc. grew its stake in Kezar Life Sciences by 520.0% in the 1st quarter. Franklin Resources Inc. now owns 2,026,900 shares of the company’s stock valued at $8,837,000 after buying an additional 1,700,000 shares during the last quarter. BlackRock Inc. grew its stake in Kezar Life Sciences by 97.8% in the 1st quarter. BlackRock Inc. now owns 1,797,894 shares of the company’s stock valued at $7,839,000 after buying an additional 889,098 shares during the last quarter. Victory Capital Management Inc. grew its stake in Kezar Life Sciences by 176.5% in the 1st quarter. Victory Capital Management Inc. now owns 1,370,027 shares of the company’s stock valued at $5,973,000 after buying an additional 874,576 shares during the last quarter. Bellevue Group AG grew its position in Kezar Life Sciences by 20.5% in the 2nd quarter. Bellevue Group AG now owns 4,241,940 shares of the company’s stock worth $21,973,000 after purchasing an additional 723,051 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. acquired a new stake in Kezar Life Sciences in the 2nd quarter worth $3,108,000. Institutional investors own 48.45% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.

Featured Article: Why do analysts give a neutral rating?

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.